Merck and Moderna’s mRNA cancer vaccine cuts melanoma recurrence by 42% in Phase III trial

Trial results and efficacy

Merck and Moderna’s Phase III trial for intismeran autogene, a personalized mRNA cancer vaccine, demonstrated significant efficacy in reducing melanoma recurrence. The vaccine, combined with Keytruda (pembrolizumab), reduced the risk of melanoma recurrence or death by 42% over two years, compared to Keytruda alone. Additionally, 82.2% of patients receiving the combination were cancer-free after two years, versus 70% of those treated with Keytruda only.

The trial, codenamed INTerpath-001, involved 1,137 patients with high-risk melanoma (stages 2B to 4). The vaccine targets up to 34 neoantigens—unique proteins produced by cancer cells as they mutate—tailoring the treatment to each patient’s tumor. The combination also reduced the risk of distant metastasis or death by 38%, according to the findings.

Safety and regulatory outlook

The treatment appeared to be safe, with no new safety signals observed in the trial. Most adverse effects were attributed to Keytruda, which is known to cause side effects such as fatigue and muscle pain. The companies released the results ahead of schedule after a third party allegedly leaked the data early.

Intismeran autogene is positioned to become the first next-generation cancer vaccine to gain regulatory approval. Its success could pave the way for broader adoption of personalized mRNA-based therapies in oncology.

Expansion to other cancers

Merck and Moderna are already testing intismeran in late-stage trials for other cancers, including non-small cell lung cancer. The vaccine’s ability to train the immune system to recognize tumor-specific neoantigens could make it a versatile tool for treating multiple cancer types.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

The success of intismeran autogene in Phase III trials is a significant milestone for personalized cancer treatment. For founders and operators in biotech, this validates the potential of mRNA technology beyond infectious diseases and into oncology. The trial’s results suggest that combining mRNA vaccines with immunotherapies could become a standard approach for high-risk cancers, potentially reshaping treatment paradigms.

Regulatory approval for intismeran could also accelerate the development and approval of similar neoantigen-based therapies, reducing barriers for future innovations in this space. The trial’s strong efficacy data may attract further investment into personalized medicine, particularly for therapies targeting neoantigens. This could open opportunities for startups working on precision oncology or novel delivery mechanisms for mRNA therapies.

Key takeaways

• This breakthrough demonstrates the potential of personalized mRNA technology in oncology, potentially accelerating similar therapies for other cancers.
• Regulatory approval for intismeran could set a precedent for faster approvals of neoantigen-based therapies.
• Founders in biotech and oncology should note the growing viability of combining mRNA vaccines with immunotherapies for high-risk cancers.
• The trial’s success may influence investment trends toward personalized medicine and next-generation cancer treatments.

Related on Lazyfounder

• More health news